Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells by Masato Eitaki et al.
Eitaki et al. BMC Cancer 2012, 12:469
http://www.biomedcentral.com/1471-2407/12/469RESEARCH ARTICLE Open AccessVincristine enhances amoeboid-like motility via
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Background: Anti-cancer drugs are widely used in cancer treatment frequently combined with surgical therapy
and/or radiation therapy. Although surgery and radiation have been suggested to facilitate invasion and metastasis
of tumor cells in some cases, there is so far little information about the effect of anti-cancer drugs on cellular
invasive ability and metastasis. In this study, using four different anti-cancer drugs (vincristine, paclitaxel, cisplatin
and etoposide), we examined whether these drugs influence the invasive ability of tumor cells.
Methods: Human gastric adenocarcinoma MKN45 cells were used to evaluate the effect of anti-cancer drugs. After
drug treatment, cellular invasive ability was assessed using the Matrigel invasion chamber. Cytoskeletal changes
after treatment were examined microscopically with F-actin staining. In addition, we monitored cellular motility in
3D matrigel environment by time-lapse microscopic analysis. The drug-induced activation of RhoA and ROCK was
evaluated by pull-down assay and Western blotting using an antibody against phosphorylated myosin light chain
(MLC), respectively. Where necessary, a ROCK inhibitor Y27632 and siRNA for guanine nucleotide exchange
factor-H1 (GEF-H1) were applied.
Results: Among all drugs tested, only vincristine stimulated the invasive ability of MKN45 cells. Microscopic analysis
revealed that vincristine induced the formation of non-apoptotic membrane blebs and amoeboid-like motility.
Vincristine significantly enhanced RhoA activity and MLC phosphorylation, suggesting the involvement of RhoA/
ROCK pathway in the vincristine-induced cytoskeletal reorganization and cellular invasion. Furthermore, we found
that Y27632 as well as the siRNA for GEF-H1, a RhoA-specific activator, attenuated MLC phosphorylation, the
formation of membrane blebs and the invasive ability after vincristine treatment.
Conclusions: These results indicate that vincristine activates GEF-H1/RhoA/ROCK/MLC signaling, thereby promoting
amoeboid-like motility and the invasive ability of MKN45 cells.Background
Metastasis is one of the most fatal aspects of cancer. In
order to improve the status of cancer patients, consider-
ation for metastasis and invasion is necessary. In general,
cancer treatment is carried out by single or combined
therapy of anti-cancer drugs, surgery and ionizing radi-
ation. However, surgery and radiotherapy have been
reported to have a risk of undesirable metastasis or inva-
sion [1-4]. For example, Zhai et al. have suggested that
radiation enhances the invasiveness of glioblastoma cells* Correspondence: inanami@vetmed.hokudai.ac.jp
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reproduction in any medium, provided the or[5]. In addition to the risk of surgery- and radiation-
induced tumor metastasis, an anti-cancer drug doxo-
rubicin, which intercalates into DNA and inhibits DNA
topoisomerase II, has been reported to stimulate metas-
tasis and invasion of tumor cells via transforming growth
factor-β (TGF-β) signaling in breast cancer cells [3,6].
Because anti-cancer drugs influence various signal trans-
duction pathways other than those associated with
tumor growth and cell death, it might be possible that
they enhance metastasis or invasion as their side effects.
Currently, many anti-cancer drugs are available and
they have a variety of action mechanisms. These include
microtubule perturbation by vincristine and paclitaxel,
DNA crosslinking by cisplatin, and the inhibition oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mechanisms of anti-cancer drugs are distinct depending
on the drugs, there are studies reporting the various
types of anti-cancer drugs to influence tumor cell motil-
ity and metastasis. For example, microtubule agonists
such as paclitaxel and vincristine have been shown to
affect cellular motility [7-11]. Vinca alkaloids including
vincristine were shown to inhibit directional migration
via the abolishment of the cytoplasmic microtubule
complex in mouse fibrosarcoma MO4 cells [8]. Paclitaxel
was reported to decrease invasion and metastasis via the
inhibition of extracellular matrix degrading factors in
human prostatic PC-3 ML cells and human ovarian
Ovcar-3 cells [10,11]. In addition, Mashino et al. have
demonstrated that etoposide inhibits cellular invasion by
the induction of a metastasis suppresser gene KAI1 in
several cells including human lung adenocarcinoma
A549 cells [12].
Each cancer is unique and heterogeneous, and differ-
ent types of cancer respond differently to therapeutic
modalities. For some cancers, survival rates after radio-
therapy are high (for example, early stage larynx cancer
and non-small-cell lung cancer), whereas for many other
cancers they are not (for example, glioblastoms and sar-
comas) [13]. For chemotherapy, because some cancers
are susceptible to specific types of anti-cancer drugs
while others are not, they are prescribed depending on
their efficacy to the types of the cancer to be treated. For
example, it has been reported that breast cancer
responds well to 5-fluorouracil while cholangiocarci-
noma doesn’t [14,15]. Among all human cancers, gastric
cancer is the second frequent type of cancer in the
world, and the rate of incidence varies with area, espe-
cially high in Asia, South America and Eastern Europe
[16]. Although locally circumscribed tumors can be trea-
ted with surgery, radiation and/or endoscopic proce-
dures, majority of patients develop metastases at some
point during the course of their illness [16]. Metastatic
tumors can be treated only with systemic chemotherapy,
but some chemotherapeutic drugs such as doxorubicin
promote metastasis in certain conditions as described
above [3,6]. Nevertheless, the effect of anti-cancer drugs
on the metastatic activity of gastric cancer cells has been
hardly investigated. In this study, to determine the rela-
tionship between anti-cancer drugs and the metastatic
activity of tumor cells, we examined whether four differ-
ent types of anti-cancer drugs (vincristine, paclitaxel, cis-
platin and etoposide) could influence the invasive ability
of gastric adenosarcoma MKN45 cells.
Methods
Reagents
Vincristine, paclitaxel, cisplatin, etoposide and Y27632
were purchased from Wako Pure Chemical Co. (Osaka,Japan). Alexa Fluor 488 phalloidin and TRITC phalloidin
were purchased from Invitrogen (Carlsbad, CA) and
Sigma-Aldritch (St. Louis, MO), respectively. WST-1
and 1-methoxy PMS were purchased from Dojindo
(Kumamoto, Japan).Antibodies
The following antibodies were used: cleaved caspase-3
(#9661; Cell Signaling Technology, Beverly, MA), RhoA
(ARH03; Cytoskeleton, Denver, CO), MLC (#3672; Cell
Signaling Technology), phosphorylated MLC (pMLC)
(#3671; Cell Signaling Technology), GEF-H1 (#4076; Cell
Signaling Technology) and actin (sc-1615; Santa Cruz
Biotechnology, Santa Cruz, CA).Cell culture
Human gastric adenocarcinoma MKN45 cells were
maintained in RPMI1640 medium (Invitrogen) contain-
ing 10% fetal bovine serum (FBS) (RPMI1640/10% FBS)
at 37°C in a humidified atmosphere of 5% CO2.Invasion assay
Cellular invasive ability was evaluated using a BD Bio-
Coat™ Matrigel™ Invasion Chamber (8 μm pore size, 24-
well plate, BD Biosciences, Billerica, MA). Cells (1 × 106)
were suspended in 500 μl of serum-free RPMI1640 with
or without drugs, and they were loaded into the upper
chamber, followed by the addition of 750 μl of RPMI1640/
10% FBS into the lower chamber. After incubation for 24
h at 37°C in a humidified atmosphere containing 5% CO2,
non-invading cells were removed from the upper side of
the membrane using cotton tips. Invading cells on the
lower side of the membrane were fixed with 100% metha-
nol, and stained with 1% toluidine blue and 1% sodium
borate. All the invading cells were counted using a light
microscope.WST-1 assay
Cells (1 × 104 per well) were seeded into each well of a
96-well plate in 100 μl of RPMI1640/10% FBS with or
without drugs. After incubation for 24 h at 37°C in a 5%
CO2 humidified atmosphere, 10 μl of WST-1 solution
(3.24 μg/μl WST-1, 70 ng/μl 1-Methoxy PMS, and 20 mM
HEPES-NaOH [pH 7.4]) was added to each well. The cells
were incubated for 1 h at 37°C in a humidified atmosphere
containing 5% CO2, and the absorbance of each well was
recorded at 450 nm using a Model 680 Microplate Reader
(Bio-Rad Laboratories, Hercules, CA). Cell viability was
expressed as a percentage relative to the absorbance
obtained from the well containing non-treated control
cells.
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Cells (2.5 × 105 per well) were suspended in 2 ml of
serum-free RPMI1640 with or without drugs, and seeded
on coverslips coated with 1% gelatin. After incubation
for 24 h at 37°C in a humidified atmosphere containing
5% CO2, cells on the coverslips were fixed with 3.7%
paraformaldehyde for 15 min at room temperature, and
permeabilized with 0.2% Triton X-100 for 15 min, fol-
lowed by blocking with 1% bovine serum albumin (BSA)
for 30 min. The specimens were incubated with 2.5%
Alexa Fluor 488 phalloidin containing 1% BSA and 0.1%
Triton X-100 for 20 min, followed by staining with 300
nM DAPI for 5 min. After mounting, fluorescence im-
aging was performed with an LSM 700 confocal micro-
scope (Carl Zeiss, Oberkochen, Germany) controlled by
the Zeiss Efficient Navigation software with a ×100 ob-
jective lens.
Detection of apoptotic cells with membrane blebs
Cells were seeded on gelatin-coated coverslips and
incubated overnight. The cells were treated with vehicle,
15 μM vincristine or 100 μM etoposide. After treatment,
they were fixed with 3.7% paraformaldehyde and stained
with an anti-cleaved caspase-3 antibody, TRITC phal-
loidin and DAPI.
Time-lapse imaging
Cells (1.25 × 104) were suspended in 25 μl of serum-free
RPMI1640 with or without 30 μM vincristine, and mixed
with 25 μl of Matrigel (BD Biosciences). The cell suspen-
sion (25 μl) was dropped on a 35 mm glass-bottom dish
using a chilled pipette tip, and was spread flat by putting a
15 mm glass coverslip on it. After gelating the Matrigel by
incubating for 5 min at 37°C in a 5% CO2 humidified
atmosphere, 2 ml of RPMI1640/10% FBS was added to the
dish. The cells moving in the Matrigel were monitored at
37°C in a humidified atmosphere containing 5% CO2
using an ECLIPSE TE2000-E microscope (Nikon, Tokyo,
Japan) with a ×100 objective lens and a RETIGA EXi
FAST 1394 CCD digital camera (Qimaging, Burnaby,
Canada). Differential interference contrast (DIC) images
were acquired every minute for 1 h. Time-lapse movies
(1 h per 9.15 sec) were created using an Windows Movie
Maker software.
RhoA activity assay
RhoA activity was evaluated using a RhoA activation
assay kit (BK036; Cytoskeleton) according to the manu-
facturer's instructions. After starvation for 24 h in
serum-free RPMI1640, cells were treated with or without
vincristine up to 60 min at 37°C in a humidified atmos-
phere containing 5% CO2. The cells were then rinsed
with ice-cold PBS and suspended in 400 μl of cell lysis buf-
fer A (50 mM Tris–HCl [pH 7.5], 10 mM MgCl2, 0.5 MNaCl, 2% Igepal CA-630, 1 mM PMSF, 10 μg/ml leupeptin,
10 μg/ml aprotinin and 10 μg/ml pepstatin). Cell
lysates were centrifuged for 2 min at 10,000 g, and
supernatants were collected. Rhotekin beads (33.3 μg)
were added to the cell extracts (2 mg protein in 1 ml of
cell lysis buffer A) and they were rotated for 1 h at 4°C.
After washing the beads with wash buffer (25 mM Tris–
HCl [pH 7.5], 30 mM MgCl2, and 40 mM NaCl), proteins
were released from the beads by boiling for 2 min in 15 μl
of 2× Laemmli sample buffer (0.125 M Tris–HCl [pH 6.8],
10% β-mercaptoethanol, 4% SDS, 20% glycerol, and 0.004%
bromophenol blue). The proteins were separated by
SDS-PAGE, transferred to membranes, and analyzed by
Western blotting using an anti-RhoA antibody (1:500 dilu-
tion) for active RhoA. The remaining extracts (50 μg) were
also analyzed by Western blotting with the anti-RhoA
antibody for total RhoA.
MLC phosphorylation
After starvation for 24 h in serum-free RPMI1640, cells
were treated with or without vincristine up to 60 min at
37°C in a humidified atmosphere containing 5% CO2.
The cells were then rinsed with ice-cold PBS and sus-
pended in 100 μl of cell lysis buffer B (30 mM HEPES-
NaOH [pH 7.4], 100 mM NaCl, 20 mM NaF, 40 mM
Na4P2O7, 1 mM Na3VO4, 1 mM EGTA, 1% Triton
X-100, 1 mM PMSF, 10 μg/ml leupeptin, 10 μg/ml apro-
tinin and 10 μg/ml pepstatin). Cell lysates were centri-
fuged for 15 min at 20,000 g, and supernatants were
collected. Extracts (80 μg) were separated by SDS-PAGE,
transferred to membranes, and analyzed by Western
blotting using an anti-MLC antibody (1:1000 dilution) or
anti-pMLC antibody (1:1000 dilution).
RNA interference
GEF-H1 Stealth Select RNAi™ siRNA (HSS113587, Invi-
trogen) and Stealth RNAi™ Negative Control Medium GC
Duplex (12935–300, Invitrogen) were used. Cells were
transfected with these siRNAs (200 pmol per 35 mm dish
or 400 pmol per 60 mm dish) using Lipofectamine 2000
(Invitrogen). At 24 h after transfection, the culture
medium was replaced with fresh RPMI1640/10% FBS.
To check the GEF-H1 expression level, transfected
cells were rinsed with ice-cold PBS and suspended in cell
lysis buffer B. Lysates were centrifuged for 15 min at
20,000 g, and supernatants were collected. Extracts
(60 μg) were separated by SDS-PAGE, transferred to
membranes, and analyzed by Western blotting using an
anti-GEF-H1 antibody (1:1000 dilution).
Statistical analysis
Values are presented as means ± S.E. of at least three
independent experiments. Statistical significance was
determined by Student’s t test, Welch’s t test or paired
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ered significant.Results
Vincristine enhances invasive ability
To examine whether four different anti-cancer drugs
(vincristine, paclitaxel, cisplatin and etoposide) affected
cellular invasive ability, we performed invasion assay.
After MKN45 cells were treated with each anti-cancer
drug, the cellular invasive ability was analyzed using the
Matrigel invasion chamber. As shown in Figure 1A,Figure 1 Invasive ability enhanced by vincristine. A. The number
of invading cells measured by the invasion assay. Cells (1 × 106)
were seeded into the upper chamber in the presence or absence of
anti-cancer drugs. After 24 h incubation, the invading cells were
fixed, and stained by toluidine blue. Total numbers of the stained
cells were counted using a microscope. Con, non-treated control;
Vin, vincristine; Pac, paclitaxel; Cis, cisplatin (15 μM); Eto, etoposide
(20 μM). The graph shows mean ± S.E. of three independent
experiments. *, P < 0.05; **, P < 0.01 versus Con. B. Cells (1 × 104)
were seeded into wells of a 96-well plate in the presence or
absence of anti-cancer drugs. After 24 h incubation and the
following 1 h incubation with WST-1 solution, the absorbance at
450 nm was recorded using a microplate reader. Cell viability is
expressed as percentages relative to the viability obtained for non-
treated control. Con, non-treated control; Vin, vincristine; Pac,
paclitaxel; Cis, cisplatin (15 μM); Eto, etoposide (20 μM). The graph
shows mean ± S.E. of three independent experiments. N.S., not-
significant.vincristine enhanced cellular invasive ability in a
concentration-dependent manner whereas paclitaxel
completely blocked it. Cisplatin and etoposide also
inhibited it significantly, but that was not as much as
paclitaxel did. Next, cell viability was evaluated by WST-1
assay to assess whether it was affected by the treatment
with the drugs. Vincristine, cisplatin and etoposide
decreased the viability of MKN45 cells about 35% com-
pared to the non-treated control, whereas paclitaxel
decreased it about 30% (Figure 1B). There was no sig-
nificant difference in the cell viability between 0.1 and
15 μM vincristine treatment. Likewise, there was no sig-
nificant difference in the cell viability between 0.1 and 15
μM paclitaxel treatment. These results indicated that
vincristine enhanced cellular invasive ability independently
of the effect on cell viability, and that microtubule
depolymerization by vincristine, neither microtubule
polymerization by paclitaxel nor DNA damage by cisplatin
and etoposide, elevated the invasive ability of MKN45
cells.
High concentration vincristine induces amoeboid-like
motility
To understand how vincristine enhanced the invasive
ability of MKN45 cells, we examined the morphology
and motility of the vincristine-treated cells. Recently, it
has been demonstrated that cancer cells display two dif-
ferent modes of cell motility, namely, mesenchymal
motility and amoeboid-like motility, in an in vitro
3D environment as well as in vivo [17-19]. Mes-
enchymal motility is characterized by the elongated
cellular morphology with cell protrusions, the integrin-
dependent adhesion to extracellular matrix (ECM), and
the degradation of the ECM by matrix metalloprotei-
nases (MMPs) [20-23]. On the other hand, amoeboid-
like motility is characterized by the rounded cellular
morphology with membrane blebs, less adhesiveness to
ECM, and the MMP-independent invasion through gaps
of the ECM by squeezing [24-27]. To analyze the effect
of vincristine on the cytoskeleton, F-actin was labeled
with Alexa Fluor 488 phalloidin after vincristine treat-
ment. As shown in Figure 2A, non-treated control
cells formed numerous cell protrusions, which are often
associated with mesenchymal motility. While 0.1 μM
vincristine and 15 μM paclitaxel caused the reduction
of cell protrusions, 15 μM vincristine induced the
formation of membrane blebs, a hallmark of amoeboid-
like motility.
Because membrane blebbing is frequently associated
with apoptosis, we examined whether the vincristine-
induced blebbing cells were apoptotic. The cells after
drug treatment were co-stained with phalloidin and
cleaved caspase-3 antibody to detect blebbing cells and
apoptotic cells, respectively. We observed that etoposide
Figure 2 Amoeboid-like motility observed after vincristine treatment. A. Cellular morphology after 24 h drug treatment. Cells (2.5 × 105)
were seeded into wells of 6-well plates and incubated for 24 h on gelatin-coated coverslips with or without vincristine or paclitaxel. F-actin was
labeled with Alexa Fluor 488 phalloidin, and nuclei were labeled with DAPI. F-actin (green) and nuclei (blue) were analyzed using confocal
microscopy. Arrows indicate cell protrusions. Arrowheads indicate membrane blebs. White bars, 10 μm. B. Detection of blebbing cells and
apoptosis. Cells on gelatin-coated coverslips were treated with vehicle or drugs, fixed and stained with TRITC phalloidin, cleaved caspase-3
antibody and DAPI. F-actin (red), cleaved caspase-3 (green) and DAPI (blue) were analyzed using confocal microscopy. Arrows indicate the cells
with membrane blebs. White bars, 10 μm. C. DIC images from supplemental videos of the control cell (Additional file 1: Video S1) and the 15 μM
vincristine-treated cell (Additional file 2: Video S2). Cells (6.25 × 103) were confined to a 50% Matrigel environment with or without 15 μM
vincristine on a 35 mm glass-bottom dish by a coverslip. Frames show the cells at the indicated times. Arrows indicate cell protrusions.
Arrowheads indicate membrane blebs.
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ing the induction of apoptosis by etoposide treatment
(Figure 2B). As expected, these cleaved caspase-3-
positive cells had membrane blebs. On the other hand,
vincristine treatment stimulated the formation of mem-
brane blebs, but the blebbing cells were not cleaved
caspase-3-positive. Therefore, vincristine-induced mem-
brane blebs were suggested to be independent of apoptosis.
We next investigated the cellular motility in a 3D
Matrigel environment using the time-lapse imaging
technique to monitor the mode of cellular motility dir-
ectly. We observed that non-treated cells had the mes-
enchymal motility accompanied by the cell protrusions
(Figure 2C and Additional file 1: Video S1). On the other
hand, cells treated with 15 μM vincristine showed the
amoeboid-like motility accompanied by the membrane
blebs (Figure 2C and Additional file 2: Video S2 and
Additional file 3: Video S3). These results indicated that,
at high concentration, vincristine induced amoeboid-like
motility in MKN45 cells.High concentration vincristine activates RhoA
These results prompted us to determine how vincristine
induced the formation of membrane blebs and
amoeboid-like motility. Rho GTPases have been known
to be essential for cellular motility [28-30]. Recent
reports suggest that RhoA, one of the Rho GTPases,
plays a crucial role in these events through the activation
of the downstream targets such as ROCK and MLC
[31-35]. To test whether vincristine affects RhoA activity
in MKN45 cells, we assessed it by pull-down assay.
RhoA activity increased transiently after 15 μM vincris-
tine treatment, peaking at 15 min after the treatment,
followed by a decrease to the basal level (Figure 3A).
Whereas 15 μM vincristine significantly increased RhoA
activity, 0.1 μM vincristine did not affect it (Figure 3B).
These results indicated that 15 μM vincristine stimulated
RhoA activity.Figure 3 RhoA activated by vincristine. A and B. Cells were
starved in serum-free RPMI1640 for 24 h, and then exposed to
vincristine. After vincristine treatment, the cells were harvested to
evaluate RhoA activity by rhotekin-based pull-down assay. RhoA in
pull-down samples (active RhoA) and in total lysates (total RhoA)
were detected by Western blotting using an anti-RhoA antibody. A,
time-course; B, concentration-response at 15 min. The blots in (A)
and (B) are representative of three independent experiments. The
blots were quantified by densitometry, and the results were
expressed as ratio relative to the values obtained in non-treated
control cells (0 min or 0 μM). The graphs in (A) and (B) show means ±
S.E. of three independent experiments. *, P < 0.05 versus control.High concentration vincristine promotes MLC
phosphorylation
Because it is reported that RhoA activation leads to the
phosphorylation of MLC via ROCK [33], we assessed
MLC phosphorylation in vincristine-treated cells by
Western blotting. MLC phosphorylation was increased
transiently after 15 μM vincristine treatment, peaking at
15 min, followed by a gradual decrease up to 60 min
(Figure 4A). MLC phosphorylation in cells treated with
15 μM vincristine was significantly higher than in non-
treated control cells (Figure 4B). However, 0.1 μM vin-
cristine treatment did not affect MLC phosphorylation.
These results indicated that 15 μM vincristine promoted
MLC phosphorylation.ROCK mediates vincristine-induced MLC phosphorylation,
membrane blebbing and invasive ability
To determine whether ROCK mediated vincristine-
induced MLC phosphorylation, we performed Western
Figure 4 MLC phosphorylation promoted by vincristine. A and
B. Cells were starved in serum-free RPMI1640 for 24 h, and then
treated with or without vincristine. After vincristine treatment, the
cells were harvested to evaluate MLC phosphorylation by Western
blotting. A, time-course; B, concentration-response at 15 min. The
blots in (A) and (B) are representative of three independent
experiments. The blots were quantified by densitometry, and the
results were expressed as a ratio relative to the values obtained in
non-treated control cells (0 min or 0 μM). The graphs in (A) and (B)
show means ± S.E. of three independent experiments. *, P < 0.05
versus control.
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molar vincristine significantly increased MLC phos-
phorylation, and this increase was clearly diminished by50 μM Y27632 (Figure 5A). When the effect of Y27632
on the vincristine-induced membrane blebbing was eval-
uated, it abolished the formation of membrane blebs by
vincristine (Figure 5B). In addition, we determined
whether Y27632 affected the vincristine-induced cellular
invasive ability. While Y27632 did not affect the basal in-
vasive ability of MKN45 cells, it significantly inhibited
the invasive ability in cells treated with 15 μM vincris-
tine (Figure 5C). These results indicated that vincristine
enhanced the membrane blebbing and the cellular inva-
sive ability via ROCK-mediated MLC phosphorylation.
GEF-H1 mediates vincristine-induced MLC
phosphorylation, membrane blebbing and invasive ability
Switching of the inactive (GDP-bound) form of RhoA to
the active (GTP-bound) form is catalyzed by at least 24
guanine nucleotide exchange factors (GEFs) [36]. GEF-
H1 is one of the RhoA-specific GEFs and a microtubule-
associated RhoA activator. Because GEF-H1 becomes
activated when it is released from microtubules and
microtubule depolymerization activates GEF-H1 [37-39],
we hypothesized that GEF-H1 was a key regulator of the
vincristine-induced cellular invasion in MKN45 cells. To
study the involvement of GEF-H1, endogenous GEF-H1
was down-regulated by the specific siRNA and its effect
was analyzed. After MKN45 cells were treated with con-
trol or GEF-H1-specific siRNA for 72 or 96 h, the ex-
pression level of GEF-H1 was evaluated by Western
blotting. As shown in Figure 6A, GEF-H1 siRNA clearly
reduced GEF-H1 expression. Fifteen micromolar vincris-
tine significantly promoted MLC phosphorylation in
control siRNA-transfected cells but not in GEF-H1-
depleted cells (Figure 6B). When the effect of GEF-H1
siRNA on the vincristine-induced membrane blebbing
was evaluated, it significantly decreased the proportion
of vincristine-induced blebbing cells (Figure 6C). Fur-
thermore, we determined whether GEF-H1 depletion
affected the vincristine-induced cellular invasive ability.
While 15 μM vincristine significantly enhanced invasive
ability in control siRNA-transfected cells, it did not in-
crease that in GEF-H1-depleted cells as much as in con-
trol siRNA-transfected cells (Figure 6D). These results
indicated that 15 μM vincristine enhanced the mem-
brane blebbing and the cellular invasive ability via GEF-
H1/RhoA/ROCK/MLC signaling.
Discussion
The goal of this study was to elucidate whether four dif-
ferent anti-cancer drugs (vincristine, paclitaxel, cisplatin
and etoposide) could prompt invasive ability of tumor
cells. We studied cellular invasive ability and intracellu-
lar signaling using these anti-cancer drugs in MKN45
cells, and report four main findings here. First, only vin-
cristine, but not the other anti-cancer drugs, enhanced
Figure 5 Involvement of ROCK in vincristine-enhanced invasive ability. A. Cells were starved in serum-free RPMI1640 for 24 h, and then
treated with or without 15 μM vincristine and/or 50 μM Y27632 for 15 min. The cells were then harvested to evaluate MLC phosphorylation by
Western blotting using anti-MLC and anti-pMLC antibodies. The blots in (A) are representative of four independent experiments. The blots were
quantified by densitometry, and the results were expressed as ratio relative to the values obtained in non-treated control cells. The graph in
(A) shows mean ± S.E. of four independent experiments. *, P < 0.05; **, P < 0.01. B. Cells on gelatin-coated coverslips were treated with drugs,
fixed and stained with Alexa Fluor 488 phalloidin and DAPI. F-actin (green) and nuclei (blue) were analyzed using confocal microscopy. Arrows
indicate the cells with membrane blebs. White bars, 10 μm. The graph shows means ± S.E. of three independent experiments. *, P < 0.05.
C. Cells (1 × 106) were seeded into the upper chamber with or without 15 μM vincristine and/or 50 μM Y27632. After 24 h incubation, the
invading cells were fixed and stained with toluidine blue. Total numbers of the stained cells were counted using a microscope. The graphs
show means ± S.E. of three independent experiments. *, P < 0.05.
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ond, it induced the formation of membrane blebs and
amoeboid-like motility (Figure 2). Third, it induced
GEF-H1/RhoA/ROCK/MLC signaling (Figures 3-6).
Fourth, GEF-H1 and ROCK mediated vincristine-
induced cellular invasive ability (Figures 4 and 5). These
results indicated that vincristine enhanced amoeboid-
like motility via GEF-H1/RhoA/ROCK/MLC signaling,
thereby promoting invasive ability in MKN45 cells.
Vincristine is widely used in the treatment of
leukemia, lymphoma, myeloma, glioma, solid tumors of
childhood often combined with other drugs. Lung,
breast, and cervical cancer are also treated with vincris-
tine. Vincristine is used at up to 2 mg/body in one ad-
ministration. When 2 mg vincristine is injected i.v. to apatient, its blood concentration is estimated to be within
10–400 nM for a few hours [40]. Furthermore, it was
reported that vincristine accumulated to some tissues
such as spleen, thyroid, large and small intestine, and
the local concentrations in these organs could reach to
6–70 times higher than that in blood [41]. These data
suggest that the maximum concentration of vincristine
is in the range of 0.06-28 μM in some organs of a patient
treated with 2 mg vincristine. Therefore, it is conceivable
that 15 μM vincristine, the maximum dose we used in
this study, is physiologically-achievable.
We found that vincristine enhanced cellular invasive
ability of MKN45 cells in a concentration-dependent
manner. Previously, Zhao et al. have shown that the
IC50 of vincristine (72 h treatment) in MKN45 cells is
Figure 6 Involvement of GEF-H1 in vincristine-enhanced invasive ability. A. At 72 or 92 h after transfection of GEF-H1-specific siRNA or
negative control siRNA, cells were harvested to analyze GEF-H1 expression by Western blotting using anti-GEF-H1 and anti-actin antibodies. Actin
was used as a loading control. B. At 72 h after transfection, starved cells (24 h) were treated with or without 15 μM vincristine for 15 min. The
cells were then lysed and analyzed by Western blotting. The blots were quantified by densitometry, and the results were expressed as a ratio
relative to the values of pMLC/MLC obtained in non-treated cells. The graph shows mean ± S.E. of three independent experiments. **, P < 0.01.
C. Control siRNA- or GEF-H1 siRNA-transfected cells on gelatin-coated coverslips were treated with vehicle or 15 μM vincristine. The cells were
fixed and stained with Alexa Fluor 488 phalloidin and DAPI. F-actin (green) and nuclei (blue) were analyzed using confocal microscopy. Arrows
indicate the cells with membrane blebs. White bars, 10 μm. The graph shows means ± S.E. of three independent experiments. **, P < 0.01. D. The
number of invading cells measured by invasion assay. At 72 h after transfection, cells (1 × 106) were seeded into the upper chamber with or
without 15 μM vincristine. After 24 h incubation, the invading cells were fixed, and stained with toluidine blue. Total numbers of the stained cells
were counted using a microscope. The graph shows means ± S.E. of three independent experiments. *, P < 0.05.
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stimulating effect by vincristine at as low as 1 μM after
24 h treatment (Figure 1A), which is lower than IC50,
we assume that this is not a non-specific effect of vin-
cristine. However, this finding contradicts the data that
microtubule depolymerizers inhibit cellular invasion
observed in other studies [7-9]. The concentrations of
vincristine used in our study were higher than the con-
centrations in the other studies [7-9]. Therefore, we con-
sider that one potential reason for this discrepancy in
the effect of vincristine on cellular invasiveness could be
due to the concentration of vincristine used, and only
high concentration vincristine would be able to induce
GEF-H1/RhoA/ROCK/MLC signaling, leading to high
cellular invasiveness. In addition, since the cell types and
the assay systems to measure cellular invasion used in
these studies are different from those used in this study,
we cannot exclude the possibility that these factors also
contributed to the outcome. To test the differences in
the effect of vincristine on cellular invasion among cell
types, we examined it using human lung adenocarcin-
oma A549 cells and human cervical adenocarcinoma
HeLa cells. Whereas vincristine stimulated cellular inva-
sive ability in A549 cells similar to MKN45 cells, it was
not increased in HeLa cells (data not shown). These
results suggest that the enhancement of cellular invasive
ability by vincristine is at least in part cell type-specific.
In the present study, we observed no significant differ-
ence in the cell viability in 0.1 and 15 μM vincristine-
treated cells (Figure 1B). This result is supported by the
data reported by Warlters et al. showing that 0.1 and
11 μM vincristine exhibited the same level of cell tox-
icity in MKN45 cells [43]. On the other hand, we
observed that the effects on invasive ability were signifi-
cantly different between 0.1 and 15 μM vincristine.
These results suggested that vincristine enhanced cellu-
lar invasive ability in a concentration-dependent manner
without affecting the viability in MKN45 cells.
In contrast to vincristine, paclitaxel had a strong in-
hibitory effect on cellular invasive ability (Figure 1A).
Paclitaxel has been shown to inhibit RhoA activity [44].
Because RhoA activity is required not only for amo-
eboid-like motility but also for general cellular motility
[22,30,45,46], it is possible that paclitaxel attenuated
cellular invasion by inhibiting RhoA activity. Although
both vincristine and paclitaxel act on microtubules
as anti-cancer drugs, our results indicate that they
influence cellular motility differently depending on the
effect on RhoA activity. In addition, microtubule
depolymerization is shown to activate GEF-H1 [37-39].
Therefore, paclitaxel may inhibit GEF-H1 activity
through the inhibition of microtubule depolymerization,
thereby inhibiting the signaling pathway leading to cellu-
lar motility.MLC phosphorylation induces actomyosin contrac-
tion, which is required for the formation of membrane
blebs [17,25,27,35]. As shown in Figure 2A, 15 μM vin-
cristine induced the formation of membrane blebs,
which were not observed in control cells or in the cells
treated with 0.1 μM vincristine. Consistent with this re-
sult, 15 μM vincristine induced MLC phosphorylation
whereas 0.1 μM vincristine did not (Figure 3B). There-
fore, we assume that the difference in the effects of
vincristine on the formation of membrane blebs is
attributable to MLC phosphorylation induced by GEF-
H1/RhoA/ROCK signaling. As mentioned above, micro-
tubule depolymerization activates GEF-H1 [37-39],
promoting RhoA/ROCK/MLC signaling. It is thus pos-
sible that severe depolymerization of microtubules by
15 μM vincristine, but not by 0.1 μM vincristine, stimu-
lates GEF-H1/RhoA/ROCK/MLC signaling, resulting in
the formation of membrane blebs (Figure 2A).
The functions of microtubules in amoeboid-like motil-
ity are not well understood [27]. In this study, we
showed that vincristine enhanced amoeboid-like motil-
ity. Because vincristine is a microtubule depolymerizer,
our results may provide evidence that amoeboid-like
motility does not require structural functions of micro-
tubules. This concept will be clarified by performing fur-
ther studies such as the live-cell fluorescence imaging of
microtubules in vincristine-induced amoeboid-like mov-
ing cells.
To the best of our knowledge, this is the first report to
provide evidence that GEF-H1 can regulate amoeboid-
like motility. Previous studies have reported that GEF-
H1 regulates the interaction of actin and microtubule at
the leading edge and focal adhesion turnover [47,48] that
are involved in mesenchymal motility [49,50], suggesting
the involvement of GEF-H1 in this mode of cellular mo-
tility. Considering these findings together with the role
of GEF-H1 in amoeboid-like motility that we presented
in this study, it seems likely that GEF-H1 regulates not
only mesenchymal motility but also amoeboid-like mo-
tility depending on the situation. In recent studies,
tumor necrosis factor-β and TGF-β have been reported
to promote cellular invasion and metastasis [51-54].
These cytokines have been reported to activate or up-
regulate GEF-H1 [55-57]. Additionally, radiation and
doxorubicin have been shown to induce metastasis and
invasion of tumor cells via TGF-β, [3]. Therefore, patho-
physiological conditions that increase these cytokines
such as inflammation might stimulate cellular invasion
via the activation and/or up-regulation of GEF-H1.
As described above, vincristine has been reported to
accumulate in some organs at higher concentration than
in blood after administration [41]. Given the fact that
vincristine is widely used in cancer treatment, we sur-
mise that vincristine treatment to cancer patients could
Figure 7 Summary of this study.
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organs when its local concentration increases in the clin-
ical setting. If this is the case, it would be beneficial to
inhibit GEF-H1/RhoA/ROCK/MLC signaling pathway
when treated with vincristine to prevent tumor
metastasis.Conclusions
In conclusion, as summarized in Figure 7, this study
indicates that vincristine enhances amoeboid-like motil-
ity via GEF-H1/RhoA/ROCK/MLC signaling in MKN45
cells. Our results provide a new insight into anti-cancer
drug-induced invasion of tumor cells.Additional files
Additional file 1: Video S1. (.wmv, 3.94 MB). Time-lapse image
sequence of control MKN45 cell in 3D Matrigel environment.
Additional file 2: Video S2. (.wmv, 4.55 MB). Time-lapse image
sequence of MKN45 cells treated with 15 μM vincristine in 3D Matrigel
environment.
Additional file 3: Video S3. (.wmv, 5.39 MB). Time-lapse image
sequence of MKN45 cells treated with 15 μM vincristine in 3D Matrigel
environment.
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